Portfolio

Amal Therapeutics Exit

Amal Therapeutics is developing an active immunotherapy approach for the treatment of cancer. The company is progressing a novel therapeutic cancer vaccine using proprietary vectors fused to rationally designed multi-epitopic cargo.

Management

Dr. Madiha Derouazi

Info & Contact

Address

Avenue de la Roseraie 64
1205 Geneva

In portfolio

07. Feb 2014 – 28. Jun 2019

Sector

Exit